Loading...

Biotinylated Recombinant Human CD223 (LAG-3)-Fc Chimera (carrier-free)

Pricing & Availability
Regulatory Status
RUO
Other Names
Lymphocyte activation gene 3 protein, LAG-3, Secretedlymphocyte activation gene 3 protein, sLAG3, CD223
Ave. Rating
Submit a Review
Product Citations
publications
A. Biotin-recom_human-CD223-Fc-Chimera_1_CF
Biotinylated Recombinant Human CD223 (LAG-3)-Fc Chimera induces TNFα secretion in JAWSII cells in a dose-dependent manner. ED50 of this effect is 0.08 – 0.8 µg/mL.
  • A. Biotin-recom_human-CD223-Fc-Chimera_1_CF
    Biotinylated Recombinant Human CD223 (LAG-3)-Fc Chimera induces TNFα secretion in JAWSII cells in a dose-dependent manner. ED50 of this effect is 0.08 – 0.8 µg/mL.
  • B. Biotin-recom_human-CD223-Fc-Chimera_2_CF
    Stability testing for Biotinylated Recombinant Human CD223 (LAG-3)-Fc Chimera. Biotinylated Recombinant Human CD223 (LAG-3)-Fc Chimera was aliquoted in 2 mM CHAPS, PBS pH 7.2, at 0.2 mg/mL and one aliquot was kept at 4°C (Control), and another was frozen and thawed four times (4x Freeze/Thaw). After this procedure, the samples were tested for their ability to induce TNFα secretion in JAWSII cells in a dose-dependent manner. ED50 of this effect is 0.08 – 0.8 µg/mL.
Cat # Size Price Quantity Check Availability Save
561214 25 µg 330 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
561216 100 µg 795 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Initially documented in the 1990, lymphocyte activation gene 3 (LAG-3, CD223) is an inhibitory co-receptor of the type-1 immunoglobulin family with a molecular mass of 50 kD. LAG-3 exhibits four extracellular immunoglobulin-like domains named D1 to D4, a transmembrane region and an intracellular region. Except the proline-rich loop located on D1, LAG-3 is structurally similar to the CD4 co-receptor. LAG-3 selectively interacts with the major histocompatibility complex class II (MHC II) of antigen presenting cells (APCs) and tumor cells which activate the inhibitory pathway and eventually lead to dysfunction of T-cells. LAG-3 receptors and their ligands are expressed in the tumor microenvironment and form a complex organization for cell-communication. LAG-3 receptors are present on almost all T-lymphocytes (activated CD4+ T-cells, CD8+ T-cells, FOXP3+ regulatory T-cells and Naïve T-cells), NK cells and dendritic cells (DCs). Dendritic cells express both LAG-3 receptors and their ligands and LAG-3 induced signaling promotes their maturation. LAG-3 acts synergistically with PD-1 and/or other immunoregulatory genes to prevent autoimmunity in mice. The infiltrated LAG3+ lymphocytes are associated with overall survival of TNBC and HER2+ breast cancer patients, in addition, peripheral blood LAG3+ immunotype strongly corelates with treatment responses, survival, progression-free survival in melanoma. Current existing clinical therapeutic agents targeting LAG-3 can be classified into three different groups; the LAG-3 fusion protein, the LAG-3 monoclonal antibody and the LAG-3 involving bispecific antibody. A novel combinatorial FDA approved immunotherapy uses LAG-3 blocking agent together with nivolumab (anti-PD-1 agent) for metastatic melanoma’ which may suggest future prospects of LAG-3 targeted therapies for cancer patients.

Product Details
Technical Data Sheet (pdf)

Product Details

Source
Biotinylated human CD223 (LAG-3)-Fc Chimera, amino acids Leu23-Leu450 (Accession # P18627), with a C-terminal human IgG1-Fc tag and -Avi tag, was expressed in 293E cells.
Molecular Mass
The 707 amino acid recombinant protein has a predicted molecular mass of approximately 77.09 kD. The DTT-reduced and non-reduced protein migrate at approximately 80 kD and 200 kD respectively in SDS-PAGE. The predicted N-terminal amino acid is Leu.
Purity
> 95%, as determined by Coomassie stained SDS-PAGE
Formulation
0.22 µm filtered protein solution is in 2 mM CHAPS, PBS pH 7.2
Endotoxin Level
Less than 0.1 EU per μg of protein as determined by the LAL method
Concentration
25 µg size is bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at - 20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 μg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
Activity
Biotinylated Recombinant Human CD223 (LAG-3)-Fc Chimera induces TNFα secretion in JAWSII cells in a dose-dependent manner. ED50 of this effect is 0.08 – 0.8 µg/mL.
Application

Bioassay
Application Notes

BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.

Antigen Details

Structure
Monomer
Distribution

T-lymphocytes, NK cells, and dendritic cells (DCs)

Function
T-cell dysfunction, dendritic cell maturation, role in autoimmunity
Interaction
All T-lymphocytes (activated CD4+ T-cells, CD8+ T-cells, FOXP3+ regulatory T-cells and Naïve T-cells), NK cells and dendritic cells (DCs), antigen presenting cells (APCs) and tumor cells
Ligand/Receptor
MHC II of antigen presenting cells (APCs) and tumor cells
Bioactivity
Biotinylated Recombinant Human CD223 (LAG-3)-Fc Chimera induces TNFα secretion in JAWSII cells in a dose-dependent manner. ED50 of this effect is 0.08 – 0.8 µg/mL.
Cell Type
Dendritic cells, NK cells, T cells, Tregs
Biology Area
Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References
  1. Triebel F, et al. 1990. J Exp Med. 171:1393-405.
  2. 2. Chocarro L, et al. 2021. Int. J. Mol. Sci. 17:5282.
  3. Gaikwad S, et al. 2022. Semin Cancer Biol. 86:137-150. 
  4. Avice MN, et al. 1999. J Immunol. 162:2748-53.
  5. Lecocq Q, et al. 2020. Int J Mol Sci. 22:75.
  6. Mair MJ, et al. 2021. J Neurooncol. 152:533.
  7. Datar I, et al. 2019. Clin Cancer Res. 25:4663-4673.
  8. Zeng H, et al. 2020. J Immunother Cancer. 8:e000651.
  9. Andreae S, et al. 2003. Blood. 102:2130-7.
  10. Okazaki T, et al. 2011. J Exp Med. 208:395-407.
  11. Guoming H, et al. 2023. Front Oncol. 12:986903.
  12. Shen R, et al. 2021. Sci Transl. Med. 13:eabf5107.
Gene ID
3902 View all products for this Gene ID
UniProt
View information about CD223 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11.22.2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account